Events & Presentations Upcoming Events No upcoming events at this time Past Events 43rd Annual J.P. Morgan Healthcare Conference Jan 15, 2025 at 7:30 AM PST Click here for webcast Investor Presentations ARS Pharma Corporate Presentation ARS Pharma Corporate Presentation 5.4 MB Aug 9, 2024 neffy® FDA Approval Call On August 9, 2024, we announced the FDA approval of neffy for adults and children 30 kg or greater in body weight. Supporting Materials neffy FDA Approval Call (August 2024) 5.9 MB Mar 7, 2024 at 1:00 PM EST Neffy® Investor Day On March 7, 2024, we hosted a virtual neffy Investor Day event showcasing the neffy product profile and anticipated commercialization strategy, including presentations from ARS Pharma senior management, as well as guest speakers. To view the webcast, click here Supporting Materials neffy investor day presentation (Mar 2024) 10.1 MB Scientific Publications JACI: In Practice Self-Administration Dosing Publication Adult pharmacokinetics of self-administration of epinephrine nasal spray 2.0 mg… JACI 2023 Single and Repeat Dose Publication Pharmacokinetics/pharmacodynamics of epinephrine after single and repeat admini… Scientific Presentations ACAAI Poster 2024 PK Profiles Significant Differences in Pharmacokinetic Profiles Among Epinephrine Products – What is the Mechanism for Efficacy? 579.6 KB ACAAI Poster 2024 HCP interest in neffy Healthcare Professionals Interest in neffy: A Self–Administered Epinephrine Nasal Spray Device 1.1 MB ACAAI Poster 2024 BP Increase Blood Pressure and Pulse Rate Increases Without Concomitant Epinephrine Increases During Acute Allergic Reactions 683.1 KB ACCAI Poster 2024 EPI 10 JP03 neffy, Epinephrine Nasal Spray, Development, from Pharmacokinetics and Pharmacodynamics to Real-World Data in Pediatric Food Allergy Patients 905.4 KB ACAAI Poster 2024 HF Packaging Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB ACAAI Poster 2024 BP Safety Cardiovascular Safety of Intramuscular and Intranasal Epinephrine Administration 831.2 KB ACAAI Poster 2024 EPI 18 Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy, Epinephrine Nasal Spray, Versus Intramuscular Injection During Induced Allergic Rhinitis 952.1 KB AAAAI 2024 Phase 2 Urticaria Results ARS-2 (neffy), Low-Dose Intranasal Epinephrine, Improves Urticaria Scores in Patients with Frequent Urticaria Flares: Phase 2 Study Results 567.4 KB AAAAI 2024 Epinephrine Utilization A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB AAAAI 2024 Poster CMC Comparative Stability of Three Epinephrine Products Under Extreme Temperature Conditions 514.3 KB Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
Investor Presentations ARS Pharma Corporate Presentation ARS Pharma Corporate Presentation 5.4 MB Aug 9, 2024 neffy® FDA Approval Call On August 9, 2024, we announced the FDA approval of neffy for adults and children 30 kg or greater in body weight. Supporting Materials neffy FDA Approval Call (August 2024) 5.9 MB Mar 7, 2024 at 1:00 PM EST Neffy® Investor Day On March 7, 2024, we hosted a virtual neffy Investor Day event showcasing the neffy product profile and anticipated commercialization strategy, including presentations from ARS Pharma senior management, as well as guest speakers. To view the webcast, click here Supporting Materials neffy investor day presentation (Mar 2024) 10.1 MB Scientific Publications JACI: In Practice Self-Administration Dosing Publication Adult pharmacokinetics of self-administration of epinephrine nasal spray 2.0 mg… JACI 2023 Single and Repeat Dose Publication Pharmacokinetics/pharmacodynamics of epinephrine after single and repeat admini… Scientific Presentations ACAAI Poster 2024 PK Profiles Significant Differences in Pharmacokinetic Profiles Among Epinephrine Products – What is the Mechanism for Efficacy? 579.6 KB ACAAI Poster 2024 HCP interest in neffy Healthcare Professionals Interest in neffy: A Self–Administered Epinephrine Nasal Spray Device 1.1 MB ACAAI Poster 2024 BP Increase Blood Pressure and Pulse Rate Increases Without Concomitant Epinephrine Increases During Acute Allergic Reactions 683.1 KB ACCAI Poster 2024 EPI 10 JP03 neffy, Epinephrine Nasal Spray, Development, from Pharmacokinetics and Pharmacodynamics to Real-World Data in Pediatric Food Allergy Patients 905.4 KB ACAAI Poster 2024 HF Packaging Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB ACAAI Poster 2024 BP Safety Cardiovascular Safety of Intramuscular and Intranasal Epinephrine Administration 831.2 KB ACAAI Poster 2024 EPI 18 Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy, Epinephrine Nasal Spray, Versus Intramuscular Injection During Induced Allergic Rhinitis 952.1 KB AAAAI 2024 Phase 2 Urticaria Results ARS-2 (neffy), Low-Dose Intranasal Epinephrine, Improves Urticaria Scores in Patients with Frequent Urticaria Flares: Phase 2 Study Results 567.4 KB AAAAI 2024 Epinephrine Utilization A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB AAAAI 2024 Poster CMC Comparative Stability of Three Epinephrine Products Under Extreme Temperature Conditions 514.3 KB Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
Significant Differences in Pharmacokinetic Profiles Among Epinephrine Products – What is the Mechanism for Efficacy? 579.6 KB
Healthcare Professionals Interest in neffy: A Self–Administered Epinephrine Nasal Spray Device 1.1 MB
Blood Pressure and Pulse Rate Increases Without Concomitant Epinephrine Increases During Acute Allergic Reactions 683.1 KB
neffy, Epinephrine Nasal Spray, Development, from Pharmacokinetics and Pharmacodynamics to Real-World Data in Pediatric Food Allergy Patients 905.4 KB
Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB
Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy, Epinephrine Nasal Spray, Versus Intramuscular Injection During Induced Allergic Rhinitis 952.1 KB
ARS-2 (neffy), Low-Dose Intranasal Epinephrine, Improves Urticaria Scores in Patients with Frequent Urticaria Flares: Phase 2 Study Results 567.4 KB
A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB
